12:00 AM
 | 
Mar 30, 2009
 |  BC Week In Review  |  Clinical News  |  Regulatory

Custom NX DES System regulatory update

Xtent received CE Mark approval in the EU for its Custom NX DES System to treat coronary...

Read the full 62 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >